Physician profile
Maen Nusair
NPI 1942393137
$13,654.80
in general payments reported to CMS, 2019-2025
37 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,670 · 2020: $637 · 2021: $628 · 2022: $3,802 · 2023: $3,439 · 2024: $2,158 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,608 · Travel and Lodging: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,607.88 |
| Travel and Lodging | $1,310.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,415.94 | 2019-2025 | Watchman Access System, Avvigo Guidance System, Watchman Flx |
| Edwards Lifesciences Corporation | $2,781.33 | 2019-2025 | Sapien 3 Ultra Resilia, Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Philips North America LLC | $1,648.68 | 2021-2023 | |
| Abiomed | $826.61 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $555.61 | 2023-2025 | |
| Amgen INC. | $477.62 | 2020-2025 | Repatha, Repatha |
| Abbott Laboratories | $420.27 | 2019-2025 | Cardiomems, Amplatzer Talisman, Navitor |
| Medtronic, INC. | $364.33 | 2021-2025 | Symplicity G3, Concertotm, Corevalve Evolut R |
| Pfizer INC. | $363.98 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.04 | 2023-2025 | Jardiance |
| Biosense Webster, INC. | $269.76 | 2022-2025 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $217.10 | 2019-2025 | Eliquis, Camzyos |
| Chiesi USA, INC. | $172.62 | 2022-2024 | Kengreal, Cleviprex |
| Shockwave Medical, INC | $171.74 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Surmodics, INC. | $160.79 | 2022-2024 | Pounce Venous Thrombectomy System, Pounce Thrombectomy System, Pounce Thrombectomy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $158.48 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $156.84 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $153.00 | 2022-2025 | Farxiga, Brilinta, Wainua |
| Stryker Corporation | $145.09 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Clottriever Bold Catheter |
| Teleflex LLC | $137.79 | 2023-2025 | Guideliner, Trapliner, Turnpike |
| Kiniksa Pharmaceuticals International, Plc | $130.26 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $102.75 | 2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $81.62 | 2023-2024 | Verquvo |
| Medtronic Vascular, INC. | $62.35 | 2019-2020 | |
| Livanova USA, INC. | $46.51 | 2021-2023 | Lifesparc |
| Bayer Healthcare Pharmaceuticals INC. | $45.49 | 2025 | |
| Sanofi-Aventis U.S. LLC | $36.65 | 2023 | |
| Bridgebio Pharma, INC. | $36.00 | 2025 | Attruby |
| Inari Medical, INC. | $26.81 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novo Nordisk INC | $24.66 | 2025 | Wegovy |
| Penumbra, INC. | $24.64 | 2024 | Indigo System |
| Cordis US Corp. | $24.18 | 2025 | Mynxgrip |
| Terumo Medical Corporation | $21.72 | 2019 | |
| Lantheus Medical Imaging, INC. | $19.69 | 2024 | |
| Acist Medical Systems, INC. | $18.54 | 2022 | |
| Angiodynamics, INC. | $18.18 | 2019 | |
| Cardiva Medical, INC. | $18.13 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maen Nusair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.